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Abstract: A two day meeting hosted by the World Health Organization (WHO) and the U.S. Centers for Disease Control 
and Prevention (CDC) was held in May 2006 in Entebbe, Uganda to review the laboratory performance of virologic mo-
lecular methods, particularly the Roche Amplicor DNA PCR version 1.5 assay, in the diagnosis of HIV-1 infection in in-
fants. The meeting was attended by approximately 60 participants from 17 countries. Data on the performance and limita-
tions of the HIV-1 DNA PCR assay from 9 African countries with high-burdens of HIV/AIDS were shared with respect to 
different settings and HIV- subtypes. A consensus statement on the use of the assay for early infant diagnosis was devel-
oped and areas of needed operational research were identified. In addition, consensus was reached on the usefulness of 
dried blood spot (DBS) specimens in childhood as a means for ensuring greater accessibility to serologic and virologic 
HIV testing for the paediatric population. 
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INTRODUCTION 
  Targets for the treatment of paediatric HIV infection are 
not being met in many African countries despite the increas-
ing availability of the appropriate drugs needed for antiretro-
viral therapy (ART). African children infected with HIV are 
dying at an alarming rate. A meta-analysis published in 2004 
showed that with no intervention approximately 35% of HIV 
infected children in Africa died before one year of age and 
that more than 52% died before their second birthday [1]. 
Data from Zambia demonstrated that 30-50% of infected 
infants died by two years of age [2] and recently published 
studies from South Africa found that 40% of HIV-infected 
infants died by 12 months of age [3, 4]. Additionally, these 
South African studies showed that over a 24 month period 
60% of all infants were lost to follow-up by 6 weeks of age 
and 85% by 12 months, suggesting that one reason HIV-
infected infants are not receiving timely access to ART is 
because most are not routinely accessing mother-child health 
(MCH) services early and HIV infection is not detected in a 
timely manner. It is critical to provide accurate and early 
infant diagnosis of HIV infection to ensure that comprehen-
sive care and treatment including ART is offered to eligible 
infants, to evaluate prevention of mother-to-child transmis- 
sion (PMTCT) programs, and to facilitate appropriate strati-
fication of healthcare services [5]. 
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  Results of serologic HIV-1 diagnostic assays, the most 
widely used tools for diagnosing HIV infection, are difficult 
to interpret in infants and young children due to the persis-
tence of maternal HIV antibodies for up to 18 months. As an 
alternative, the World Health Organization (WHO) and the 
United Nations International Children’s Emergency Fund 
(UNICEF) have recommended that countries provide access 
to virologic testing for HIV-exposed infants. To support na-
tional plans for scale-up of early infant diagnosis (EID) pro-
grams, high-burden countries are seeking guidance on choos-
ing the appropriate technologies and testing algorithms using 
virologic or molecular assays. In the South African setting, it 
was shown that a single HIV DNA Polymerase Chain Reac-
tion (PCR) test at 6 weeks of age was more useful to identify 
HIV infection among HIV exposed infants for early care and 
treatment than performing HIV enzyme immunosorbant as-
says (ELISA) at 12 months of age [1, 6]. However, factors in 
addition to cost, such as selection of who will be tested and 
when and where testing will be performed, have a direct im-
pact on the choice of technology. 
METHODS 
  To address the need for scaling up HIV early infant diag-
nostic efforts the World Health Organization (WHO) and the 
U.S. Centers for Disease Control and Prevention (CDC) held 
a meeting in May 2006 in Entebbe, Uganda, attended by 60 
participants from 17 countries. The goals of the meeting 
were to review the characteristics of available assays and 
share existing data on their performance in 9 African coun-
tries with high-burdens of HIV/AIDS including infections Role of the Laboratory in Ensuring Global Access to ARV Treatment for HIV-Infected Children  The Open AIDS Journal, 2008, Volume 2    18
with different HIV subtypes; to discuss limitations of these 
assays in program settings, to identify areas where targeted 
operational research is needed to improve the performance of 
assays; and to develop consensus statements on the use of 
virologic assays for EID. 
RESULTS AND DISCUSSION 
Available Testing Methodologies for Early Infant Diag-
nosis of HIV Infection 
  A variety of commercially-available assays are currently 
in use including HIV DNA PCR [7]; HIV RNA assays [8-
10] and the ultra-sensitive HIV p24 antigen assay [11] as 
well as in-house PCR assays that have been validated and are 
appropriately quality-assured. Although in-house, non-
commercial, PCR assays can be validated according to the 
process recommended by the WHO [12], commercially 
available assays, while being more costly, offer the most 
suitable option for rapid scale-up of early infant diagnosis 
because they offer standardized reagents and adequate pro-
duction and availability. 
  To address the utility of diagnostic technologies in early 
infant diagnosis in the meeting a variety of technologies 
were reviewed. The features of these technologies were 
summarized in Table 1. These technologies include 1) Roche 
Amplicor HIV-1 Monitor™ and Manual Cobas Taqman 
[13]; 2) Abbott Real-Time HIV-1 [14]; 3) Bayer Versant
® 
HIV-1 RNA 3.0 [15]; 4) bioMerieux NucliSens
® HIV-1 QT 
and Nuclisens EasyQ HIV-1 [16]; 5) the qualitative Am-
plicor HIV DNA PCR v1.5 assay [7]; 6) Cavidi Exavir
® 
Load assay; and 7) the Perkin Elmer Ultra-sensitive HIV-1 
p24 antigen assay [17]. 
  The use of dried blood spot (DBS) specimens as the pri-
mary specimen for EID was an important topic for discus-
sion during the meeting. DBS use represents a paradigm shift 
in accessibility to virologic testing for HIV infection. In ad-
dition to antibodies, nucleic acids in DBS have been shown 
to be stable for several months at ambient temperatures, pro-
vided the DBS specimens have been thoroughly dried and 
are stored with desiccant. Thus DBS specimens can be col-
lected at remote rural sites and transported to a central or 
regional testing laboratory. However, specific training in the 
collection, labelling, drying and packaging of DBS is re-
quired to guarantee the quality of specimens for molecular 
analysis. In some countries with large-scale HIV counselling 
and testing programs, DBS specimens are used for routine 
quality control (QC) of rapid HIV serologic testing and thus 
healthcare staff have already been trained in the proper 
preparation and handling of DBS. 
  Supplies for DBS collection and shipment can be diffi-
cult to procure and several participants commented on the 
potential usefulness of a premade DBS sample collection kit 
containing all the necessary supplies for health care facilities. 
The precise contents of each kit for use in infant diagnosis or 
quality control of HIV testing would need to be determined 
for each country. Although other filter papers have been used 
for blood collection, Whatman 903 specimen collection pa-
per (previously known as Schleicher and Schuell 903 paper) 
is the most widely used and validated paper for DBS collec-
tion. 
Role of HIV Antibody Assays in Children Less Than 18 
Months of Age 
  HIV antibody tests (either rapid tests or ELISA) are the 
preferred means of diagnosis of HIV infection in children 
older than 18 months of age. In contrast, a positive HIV an-
tibody test at less than 18 months should not be used as the 
primary assay for EID because of the likelihood that the ma-
ternal antibodies might still be present. However, when per-
Table 1.  Commercial Assays Can Potentially be Used for Diagnosis of HIV Infection in Infants and Young Children 
 
Source/Name of Assay  Sample Used  Assay/Target   Volume (in ml)  Cost Per Test ($) 
Roche 
Amplicor HIV-1 
DNA v1.5 
Whole Blood  Qual/DNA 0.5  35-  90 
Roche 
Amplicor HIV-1 Monitor v 1.5 manual 
Plasma or serum  Quan/RNA  0.2-0.5  20-50 
RocheCobas Amplicor HIV-1 Monitor v 1.5  Plasma or serum  Quan/RNA  0.2-0.75  20-50 
Roche 
TagMan 48 
Plasma or serum  Quan/RNA  0.5-1  50 
Bayer 
Versant 
HIV-1 RNA 
Plasma or serum  Quan/RNA   1  85-90 
Biomerieux NucleiSens EasyQ  Plasma or serum  Quan/RNA  1  80 
Abbott 
Real Time HIV 
Plasma or serum  Quan/RNA  0.2-1  20-70 
CavidiExaVir Load  Plasma or serum  Quan/ 
RT 
1 13-15 
Perkin Elmer 
Up24 antigen  Plasma or serum 
Quan/ 
p24 antigen 
50 l 10 
*Qual- Qualitative and **Quan- Quantitative. 19    The Open AIDS Journal, 2008, Volume 2  Stevens et al. 
formed according to robust national algorithms that accu-
rately and reliably detect HIV antibody, a positive rapid test 
should trigger virologic or molecular testing. A study ad-
dressing the potential use of rapid HIV tests prior to molecu-
lar testing for early screening of pediatric HIV infection in 
Uganda was presented at the meeting [18]. The rationale 
behind this approach is that although a rapid test cannot es-
tablish that an infant is infected because the test cannot dis-
tinguish maternal from infant antibodies, it may be able to 
establish that the infant is uninfected since a close correla-
tion had been observed between a negative rapid test result at 
any age and a negative test result by molecular assays. In the 
Uganda study, it was reported that the correlation was per-
fect in 138 healthy infants attending an immunization clinic, 
but at a pediatric AIDS clinic, only 49/57 (86%) of infants 
ranging in age from 6 weeks to 18 months were correctly 
identified as uninfected by an HIV-negative rapid test. Eight 
infected rapid test-negative infants had either a detectable 
viral load or HIV p24 antigen; and one of these infants was 
HIV antibody positive when re-tested using a different rapid 
test. A potential reason for these undetected infections is that 
rapid HIV testing may have been performed during the win-
dow period for the antibody response, thus implicating 
breastfeeding as the mode of transmission particularly in the 
older infants. These results indicate that further studies are 
needed to determine the age at which rapid HIV testing of 
exposed infants would be most cost-effective in relation to 
sensitivity, specificity, and positive and negative predictive 
values. However, the following issues suggest that introduc-
ing routine rapid HIV testing in the pediatric setting should 
be considered: 1) when compared to molecular testing, rapid 
tests are simpler, cheaper and more widely available; 2) a 
substantial proportion of uninfected, HIV-exposed children 
lose maternal antibodies before 9 months; 3) early identifica-
tion and exclusion of HIV-uninfected infants could help fo-
cus limited HIV care resources on infected infants; and 4) 
breast-feeding infants can easily be retested by rapid tests 6 
weeks after weaning. Based on evidence presented at the 
meeting and preliminary data from ongoing studies a con-
sensus was reached at the meeting that if an HIV-exposed 
well child between 9 and 18 months of age had never been 
breast-fed or had stopped breast-feeding for at least 6 weeks 
and had a negative HIV rapid test result then the child should 
be considered uninfected with no further testing performed 
unless symptoms develop (Fig. 1). 
Ultra-Sensitive HIV p24 Antigen Assay 
  The ultra-sensitive HIV p24 antigen assay is an ELISA, 
not a molecular assay, and is therefore suited to health facili-
ties where serologic testing is routinely performed. The ca-
veat to this is that few laboratories in Africa have been able 
to utilize the commercial Up24 antigen assay due to issues 
related to methodology and reagent supply. Nevertheless, the 
performance of the Up24 antigen assay for HIV diagnosis in 
infants and young children has been evaluated in a number 
of studies in countries with different HIV subtypes yielding 
sensitivities and specificities ranging from 96% to 99% [19-
23]. Data from South Africa presented at the meeting con-
firmed that at 6 weeks the HIV p24 assay yielded satisfac-
tory results with a sensitivity and specificity of 97.7% and 
100% respectively when compared to HIV DNA PCR testing 
[11]. Recently Patton and colleagues confirmed the feasibil-
ity of using this assay on DBS, thus dramatically expanding 
its potential value in infant diagnosis [24]. This test uses 
washer and reader as used in a typical serologic laboratory 
and does not require thermocycler as required in PCR assays. 
The cost of the reagents is approximately 10-20 US dollars. 
A consensus was reached at the meeting that the measure-
ment of HIV-1 p24 antigen in blood is sensitive enough for 
early diagnosis of HIV infection in infants and young chil-
dren, but only if the ultra-sensitive HIV p24 antigen assay 
described by Schüpbach and colleagues is followed [25, 26]. 
Total Nucleic Acid (TNA) Real-Time, Reverse-
Transcriptase PCR Assay 
  TNA is a new approach specifically designed for use 
with infant DBS and, although still undergoing optimization 
and not commercially available, is being tested in Uganda. 
This semi-quantitative assay offers a number of potential 
benefits over commercial HIV DNA PCR assays including 
cost, increased sensitivity, increased through-put per run, 
less time to completion per run and ease of automation. An 
important feature of the TNA assay is the built-in internal 
control using a single copy human gene, RNaseP gene, to 
monitor the quality of the specimen and amplification proc-
ess [27]. Data presented at the meeting from Uganda, where 
the prevalent HIV subtypes are A, C and D, suggested that 
the TNA assay performs with 100% sensitivity and specific-
ity when compared to Amplicor HIV DNA PCR assay using 
1800 DBS specimens from infants [28]. However, further 
studies are needed in other countries, and until the assay is 
available commercially, it can only be recommended as an 
ancillary assay or research tool in those laboratories with the 
necessary infrastructure and technological competence. 
HIV Amplicor DNA PCR v1.5 Assay 
  The Roche qualitative HIV Amplicor DNA PCR v1.5 
assay provides an accurate method for identification of HIV-
1 infection in infants and young children less than 18 months 
of age and is currently the only assay with extensive valida-
tion data in Africa and extensively used in the US and 
Europe [7]. Although designed for use with whole blood, the 
DNA PCR v1.5 assay can easily be adapted for use on DBS 
and this adaptation makes it particularly useful for early in-
fant diagnosis in high-burden countries [30]. 
  Early work from South Africa using DBS specimens col-
lected from 300 infants at six weeks of age showed that the 
DNA PCR v1.5 assay performed exceptionally well with a 
sensitivity and specificity of 100% and 99.6% respectively, 
compared to the same assay conducted on fresh whole blood 
samples [30]. Preliminary data on 206 children suggested 
that DBS prepared from capillary (e.g. heel prick) versus 
venous blood also yields highly accurate results with a sensi-
tivity of 98.3% and specificity of 98.7% (G. Sherman; per-
sonal communication). Participants at the meeting from 
Uganda, Zambia, Mozambique, Kenya, Namibia, Rwanda, 
Cote d’Ivoire, Botswana and South Africa shared data dem-
onstrating the excellent performance of the DNA PCR v1.5 
assay on DBS with respect to different settings and different Role of the Laboratory in Ensuring Global Access to ARV Treatment for HIV-Infected Children  The Open AIDS Journal, 2008, Volume 2    20 
HIV subtypes including perceived limitations of this assay in 
program settings. 
  Although the reports on the performance of the assay 
were generally positive, limitations to the assay were dis-
cussed during the meeting. First, although the assay has been 
shown to detect all HIV subtypes currently described, as 
with other molecular assays, it may not be capable of detect-
ing future variants of HIV due to the virus’s ongoing evolu-
tion. Second, unlike the TNA real-time assay, there is no 
primer set that will amplify an internal control to ensure that 
DNA has been sufficiently extracted from each DBS speci-
men and is suitable for amplification. Third, as with any mo-
lecular test, there are issues related to staff expertise and 
training, instrument and space requirements, and cost. 
  Because comparison studies between DBS and whole 
blood/cell pellets using the DNA PCR v1.5 assay have been 
conducted in several countries, participants concluded that it 
is not necessary for each country to repeat these evaluations 
prior to implementation of DBS testing. Difficulties were 
described in testing DBS especially in high-volume laborato-
ries since extraction of DNA from DBS is labour-intensive, 
prone to cross-contamination and may not always be effi-
cient. Thus, it was recommended that DBS QC materials be 
included in each experimental run to ensure that the extrac-
tion procedure is effective. Strict criteria need to be estab-
lished regarding acceptance of results for each experimental 
run, and specimens with low-positive results located in wells 
adjacent to specimens with strong-positive results should be 
routinely retested. Further work in automating DBS punch-
ing and DNA extraction is needed particularly for those 
laboratories testing large numbers of specimens. 
Internal Quality Control (QC) for HIV Amplicor DNA 
PCR v1.5 
  The importance of “Good Laboratory Practice” and ade-
quate quality assurance for the DNA PCR v1.5 assay was 
strongly emphasized by all participants. As with all PCR-
based technologies, the laboratory workflow should be de-
signed to ensure that separate areas are provided for the per-
formance of the assay to reduce the risk of cross-
contamination. The need to harmonize standard operating 
 
Fig. (1). Age-Stratified diagnostic pathways for well infants known to be HIV-exposed. Different approaches are recommended for test-
ing HIV-exposed infants based on age (35). Infants between ages 6 weeks and 9 months should not be diagnosed using an HIV Rapid test 
algorithm, but should be diagnosed by HIV DNA PCR. Children between 9 and 18 months should first be tested using an HIV Rapid test 
algorithm with positive tests confirmed by HIV DNA PCR (with immediate referral for care after a positive rapid test if there are long delays 
for the confirmatory test results). In children older 18 months of age, a positive result in the HIV Rapid test algorithm is indicative of HIV 
infection. 
Ages 9 to 18 months  Older than 18 months  Ages 6 weeks to 9 months  
HIV Virologic Molecular Test (DNA PCR) 
Positive  
HIV Rapid Test Algorithm 
Negative  Positive 
If infant 
becomes unwell, 
refer to sick 
child algorithm 
(Fig. 2) 
Repeat HIV Rapid 
test 6 weeks after 
stopping breast 
feeding 
Negative  Positive 
Child is infected 
with HIV 
Child is not 
infected with HIV 
 
 (If child becomes 
unwell, refer to 
sick child 
algorithm, Fig.2)  
Negative 
Infant is infected with HIV  If positive, perform 
DNA PCR to 
confirm HIV 
infection 
If negative, infant is 
not infected with 
HIV 
HIV Rapid Test Algorithm 
Testing Algorithm for Well Infants born to HIV-infected Mothers 21    The Open AIDS Journal, 2008, Volume 2  Stevens et al. 
procedures (SOPs) across the testing laboratory network was 
highlighted to include pre- and post-analytical phases of the 
process including sample collection, labelling and tracking, 
shipping and reporting. 
  A number of innovative approaches to monitor the over-
all performance of the Roche Amplicor DNA PCR v1.5 as-
say as part of internal QC were suggested including monitor-
ing the number of internal positive control failures, the num-
ber of equivocal results and the number of false-positive and 
false-negative results as compared to a gold-standard. In 
Uganda, the Amplicor positive control failure was rare with 
this assay (1/975 specimens) and the equivocal result rate 
was low at 0.7%; false positive and false negative rates were 
0.4% and 0% respectively [27]. Data presented from South 
Africa showed that between July 2005 and April 2006, 
22,431 Roche Amplicor DNA PCR v1.5 assays were con-
ducted with a combined internal positive control failure and 
equivocal result rate of 1-2% [31]. It was noted that this rate 
increased when new staff were introduced on the bench, 
when DBS technology was initially implemented, and when 
control specimen problems were identified, all of which 
highlight the need for continuous monitoring to identify pos-
sible laboratory staff who need re-training. 
  Participants at the meeting reported a variety of testing 
algorithms in use in their countries. In Uganda, specimens 
are extracted and tested in parallel on DNA PCR v1.5 and 
TNA; re-testing on an individual assay is triggered when 
internal quality control criteria are not met, and when results 
on both assays are valid but discordant, re-testing is per-
formed on both assays. Using this algorithm, results with the 
two assays were 100% concordant after re-testing when nec-
essary. In other laboratories where an alternative assay is not 
available, a specimen giving a positive result in the DNA 
PCR v1.5 is routinely re-extracted and re-tested. Consensus 
could not be reached at this meeting on the need to repeat a 
positive test result, even when the run was validated by all 
controls. This is probably a reflection on the fact that few 
laboratories have experience with DNA PCR v1.5 of more 
than a year and it will take some time before confidence in 
the results can be established. Meeting participants were in 
agreement that to ensure quality of testing during scale-up of 
programs, a subset of the positive DBS specimens should be 
tested at the national reference laboratory preferably with the 
same assay. 
External Quality Assurance (EQA) for HIV Amplicor 
DNA PCR v1.5 
  Most laboratories represented at the meeting were al-
ready implementing Amplicor DNA PCR v1.5 testing using 
DBS, suggesting an urgent need for an external quality as-
surance (EQA) program to monitor the quality of HIV PCR 
testing on DBS. To this end, the CDC-Atlanta International 
Laboratory Branch established an EQA program early in 
2006. This proficiency testing (PT) program not only pro-
vides an external assessment of laboratory performance but 
also provides DBS specimens for internal quality control and 
technical assistance where needed. In the first round, ten 
DBS samples with varying HIV DNA content (0 to 100,000 
copies/ml) were shipped to 17 participating laboratories from 
11 different countries [32]. All laboratories participating in 
the program performed the DNA PCR v1.5 assay but used a 
variety of different DNA extraction methodologies including 
the Roche Manual Extraction, bioMerieux EasyMag and 
Roche MagNapure analysers. Of the 17 laboratories, 14 
(83%) reported results that were in complete agreement with 
the expected results. There were no false positive results, and 
all false-negative results were from DBS specimens contain-
ing low copy number of HIV-1 DNA, suggesting inefficient 
extraction of DNA from the DBS. Similar difficulties with 
false-negative results on low-positive DBS specimens were 
seen in the second round of the PT program four months 
later when the number of participants increased to 22 labora-
tories in 13 countries (L.M. Parsons, personal communica-
tion). Technical support has been provided for the laborato-
ries reporting false-negative results. It is recommended that 
all laboratories using the DNA PCR v1.5 for provision of 
early infant diagnostic services should enroll in a national or 
international EQA program. 
Large-Scale Implementation of the HIV Amplicor DNA 
PCR v1.5 
  As programs begin to scale-up, automation of the differ-
ent steps in the HIV DNA PCR v1.5 assay will need to be 
introduced and evaluated. In the South African context 
where demand for HIV DNA PCR testing is high, automa-
tion of extraction has been evaluated using the Roche Mag-
Napure Analyser. Overall, results to date have shown good 
correlation between the MagNapure extraction protocol and 
the Roche manual extraction procedure on cell pellets from 
whole blood specimens [7] but a slightly reduced sensitivity 
was seen when DBS specimens were used. The CDC-Atlanta 
International Laboratory Branch is evaluating automated 
extraction of nucleic acids from DBS with the Corbett X-
tractor Gene instrument (Corbett Robotics, Queensland, Aus-
tralia), and has found the instrument to provide rapid 
through-put with a sensitivity comparable to the Roche man-
ual extraction method (R. Downing and C.-Y. Ou, personal 
communication). 
  There is an even more pressing need to automate the 
DBS punching step prior to analysis since the manual punch-
ing of discs is a rate-limiting step in the overall procedure 
and is highly prone to cross-contamination. Meeting partici-
pants indicated the need for further validation of a semi-
automated punching instrument; the BSD 600-Duet Semi-
Automated Dried Sample Punch Instrument (BSD Robotics, 
Queensland, Australia). With this instrument discs of 6 mm 
diameter can be punched directly into the Corbett 96 deep-
well plates for automated extraction. The final step in the 
Roche DNA PCR v1.5 assay, the phase to detect colour de-
velopment, is labour intensive and time-consuming and 
meeting participants indicated the need for the manufacturer 
to develop an automated version. 
  The overall design of a national EID program is dictated 
by the capacity of the testing laboratories and such capacity 
is dependent on the test adopted. To meet the high-volume 
testing needs in South Africa, testing is done by teams of 
technicians working in shifts, 24 hours each day. In Uganda 
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fants in need of testing are born each year at least 12 testing 
facilities will be required, each with the capacity to perform 
8,000 tests annually or 160 tests per week [33]. This is be-
yond the capacity of a single technician using manual punch-
ing and extraction protocols and reinforces the urgent need 
for research into various steps needed to optimize the assay. 
Opportunities for Early Infant Diagnosis Test-
ing 
Currently, routine follow up of HIV-exposed children and 
routine paediatric HIV counselling and testing (HCT) serv-
ices are not standard in most African countries and the ma-
jority of HIV-infected infants are not identified until they 
develop symptoms and present illness at health care facili-
ties. However, there are two opportunities for HIV-infected 
mothers and hence the exposed infants to be identified before 
symptoms occur. The first is at antenatal clinic (ANC) visits 
and the second is at postnatal immunization clinics. The 
first is either poorly attended or PMTCT services are not yet 
provided. In Uganda it is estimated that only 10% of ante-
natal women have been tested and enrolled in PMTCT pro-
grams [18, 33]. In contrast, the infant immunization clinic 
visit at 6 weeks after delivery is generally well-attended and 
offers an opportunity to deliver HCT services, to identify 
infected mothers and exposed infants, and to refer them to 
care and treatment programs. The 6-week immunization 
clinic visit also coincides with the age at which the sensitiv-
ity of HIV DNA PCR assays peaks for those infants infected 
pre- or peri-natally. Further opportunities for testing exist at 
follow-up visits to the immunization clinic at 10 and 14 
weeks after delivery, though these are less-well attended. 
Linkages between ante-natal care and post-natal immuniza-
tion clinics are generally weak or non-existent in many coun-
tries. At the meeting, data from Rwanda was presented on a 
pilot study designed to improve the linkages at three health 
centers in Kigali [34]. Antenatal women who had undergone 
HCT were requested to take their ANC card coded with their 
HIV status to routine immunization clinic visits where the 
mother’s card was stapled to the infant’s immunization card. 
By using the information from antenatal services, the HIV 
exposure status was known for 68% of children attending the 
three immunization clinics. Exposed infants were started on 
cotrimoxazole, offered HIV DNA PCR testing and referred for 
ART services if the test was positive. The immunization 
clinics also offered HCT services for those mothers whose 
HIV status was unknown and ensured that HIV-positive 
mothers received ART services if this had not been initiated 
during pregnancy. The routine infant immunization visits 
served as an entry point for HIV-infected and exposed chil-
dren, and also as a ‘second chance’ to detect HIV-positive 
women not previously identified. The importance of strong 
linkages between ante-natal/post-natal clinics and ART pro-
grams for infected mothers and infants was mentioned by 
several participants. 
HIV Testing Algorithms for Infants and Young Children 
  Testing algorithms, adapted from those recently proposed 
at the WHO meeting in Geneva in April 2006 [35] are shown 
for well children less than 18 months of age (Fig. 1) and for 
sick children (Fig. 2). Although there was general agreement 
on these testing algorithms at the meeting, there was some 
debate on the advisability of using a rapid HIV antibody test 
as a ‘screening test’ because some sick children with nega-
tive serology may in fact be positive using virologic or mo-
lecular assays (Fig. 2) [18]. Further studies are needed to 
assess the sensitivity of rapid tests/algorithms against a gold-
standard ELISA testing algorithm in infants and young chil-
dren, particularly since use of rapid HIV tests offers the po-
tential for faster referral and initiation of care. At the present 
time, WHO recommends that all children known to be ex-
posed to HIV and all sick children suspected to be infected 
with HIV should be offered early virologic or molecular test-
ing if resources and infrastructure allow. 
Recommendations for Laboratory Testing for the Diag-
nosis of HIV- Infected Infants and Young Children: 
  The Roche Amplicor DNA PCR version 1.5 assay has 
been validated in many countries. The assay is standardized, 
available in kit format, has the most widespread use, and is 
therefore recommended for EID programs. In addition, DBS 
is the preferred specimen type for two reasons: ease of col-
lection from infants; and stability of DNA in the DBS during 
ambient temperature storage and shipment. Studies from 
several countries have demonstrated excellent correlation of 
results obtained using DBS and whole blood, and therefore it 
is not necessary for each country to repeat these evaluations 
prior to implementation of DBS testing. 
  The TNA assay is being used in some countries with ex-
cellent results. However, until the assay is standardized and 
available commercially, it can only be recommended as a 
confirmatory assay in those laboratories with the necessary 
infrastructure and technological competence. 
  The HIV p24 antigen assay is recommended for early 
infant diagnosis only if the ultra-sensitive protocol described 
by Schüpbach and colleagues is followed [26, 28], consistent 
supplies of test reagents could be obtained and technicians 
need to be well trained and certified to perform the assay. 
  The quantitative HIV RNA (viral load) assays are not 
currently recommended as diagnostic tools for the identifica-
tion of HIV infection in infants, since they are expensive, 
technically challenging and have not been adequately evalu-
ated using DBS specimens. Viral load assays are performed 
on whole blood specimens, and are primarily used along 
with CD4 counts for assessing disease progression, patient 
care and treatment management. However, a molecular labo-
ratory in Cote d’Ivoire has started using viral load analysis 
on whole blood samples for EID testing in spite of chal-
lenges encountered with sample collection and transportation 
from the clinical sites to the testing laboratory. While this 
laboratory has overcome these challenges, scale-up of EID 
service to remote geographic areas would not be practical 
until a careful evaluation and validation of viral load testing 
on DBS specimens is performed. 
  Before initiating EID programs, written national SOPs 
need to be developed to include pre- and post-analytical 
phases such as sample collection and tracking, shipping and 
reporting as well as the analytical phase. These SOPs should 
be widely available and staff should receive specific training 
in the collection, labelling, drying and packaging of DBS to 23    The Open AIDS Journal, 2008, Volume 2  Stevens et al. 
guarantee the quality of specimens. Supplies for DBS collec-
tion, packaging and shipment should be available in kit form 
from national procurement and distribution centers. 
  DBS specimen-rejection criteria should be established 
and if more than 2% of DBS from a specific health facility 
are rejected, this should trigger re-training of the staff re-
sponsible for specimen collection, storage and transport. 
Internal quality assurance should include monitoring the 
number of internal positive control failures, the number of 
equivocal results and the number of false-positive and false-
negative results as compared to a gold-standard. Overall 
competency of testing laboratories should be continuously 
monitored using proficiency testing panels (EQA) and by 
QC re-testing at the national referral laboratory. The overall 
performance of the laboratories supporting the national EIDP 
should be monitored by a central coordination unit within the 
Ministry of Health that will provide support supervision, and 
to which all participating laboratories should submit regular 
reports. 
ONGOING OPERATIONAL RESEARCH STUDIES 
Molecular Testing 
  The Roche HIV-1 DNA PCR assay is labour-intensive 
and time consuming. Several approaches are currently being 
evaluated for automation of different steps in this assay. 
Commercially-available HIV-1 RNA assays used for ART 
monitoring should be evaluated for possible use in the diag-
nosis of HIV infection in infants and young children, pref-
erably using DBS specimens. 
Serology 
  It would be advantageous for the management of EID 
programs to exclude HIV-uninfected children earlier than 12 
to 18 months with a simpler and less expensive rapid test. 
Research to determine the mean age at which sero-reversion 
(disappearance of maternal antibody) occurs using rapid tests 
would greatly facilitate early identification of uninfected 
children, perhaps at nine months of age or earlier. If pre-
screening with rapid tests at an earlier age is found to be use-
ful, the most appropriate rapid tests/algorithms need to be 
identified. 
Combination Algorithms 
  Studies are also needed to determine if results of rapid 
HIV serologic testing in combination with CD4+ T-cell 
count and a clinical assessment would offer a timely, cost-
effective alternative to the current algorithm of vi-
rologic/molecular testing with or without CD4 count for 
identifying infants eligible for ART. In addition, program-
matic studies should evaluate the cost-effectiveness of vari-
 
Fig. (2). Age-Stratified diagnostic pathways for sick infants where HIV exposure-status is unknown. Different approaches are recom-
mended for testing sick children based on age (34). All sick children should be tested first in an HIV Rapid test algorithm. A positive HIV 
Rapid test result in children under 18 months should be confirmed by HIV DNA PCR (with immediate referral for care after a positive rapid 
test if there are long delays for the confirmatory test results), while a positive HIV in children over 18 months of age is definitive of infection 
with HIV. 
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ous algorithms, particularly cost differences associated with 
the timing of testing. 
CONCLUSIONS 
  Accurate laboratory diagnosis of HIV-1 infection in in-
fants is necessary to initiate essential treatment, however use 
of appropriate and reliable laboratory testing is challenging 
in countries with high burdens of disease [36]. Recent re-
ports suggest that the Amplicor HIV DNA PCR version 1.5 
assay represents the best option currently available for im-
mediate scale-up of EID programs in the majority of African 
settings [2, 18, 31, 33, 34]. This assay appears to have ac-
ceptable sensitivity for the detection of the common HIV-1 
subtypes. Ongoing molecular surveillance is advised due to 
the diversity of HIV and its continuing evolution to ensure 
that molecular assays remain relevant within local popula-
tions. Continued evaluation of new technologies as they arise 
is recommended as well as significant operational research to 
ensure that the most up-to-date diagnostic algorithms are 
used. Finally, programmatic aspects have to be carefully 
considered to assure the widest possible access to HIV serv-
ices for mothers and children. 
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